Measuring in vivo tumor pHe with CEST-FISP MRI.
Paramagnetic chemical exchange saturation transfer (PARACEST) MRI contrast agents have been developed that can measure pH in solution studies, but these agents have not previously been detected in vivo. To use the PARACEST agent Yb-DO3A-oAA to measure the extracellular pH (pHe) in tumor tissue, a chemical exchange saturation transfer fast imaging with steady state precession MRI protocol was developed, the saturation period was optimized for sensitive chemical exchange saturation transfer (CEST) detection, and median filtering was used to remove artifacts in CEST spectra. These improvements were used to correlate pH with a ratio of two CEST effects of Yb-DO3A-oAA at a 7 T magnetic field strength (R(2) = 0.99, standard deviation of precision = 0.011 pH units). The PARACEST agent could not be detected in tumor tissue following i.v. injection due to the low sensitivity of in vivo CEST MRI. Yb-DO3A-oAA was detected in tumor tissue and leg muscle after directly injecting the PARACEST agent into these tissues. The measured CEST effects were used to measure a tumor pH of 6.82 ± 0.21 and a leg muscle pH of 7.26 ± 0.14, and parametric pH maps were also generated from these tissue regions. These results demonstrated that tumor pHe can be measured with a PARACEST agent and a rapid CEST-MRI protocol.
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Vipul R
VR
Sheth
Yuguo
Y
Li
Liu Qi
LQ
Chen
Christine M
CM
Howison
Chris A
CA
Flask
Mark D
MD
Pagel
D000818:Animals; D016477:Artifacts; D003287:Contrast Media / Q000737:chemistry* / Q000493:pharmacokinetics; D056831:Coordination Complexes / Q000737:chemistry* / Q000493:pharmacokinetics; D005260:Female; D006863:Hydrogen-Ion Concentration; D007089:Image Enhancement / Q000379:methods; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008325:Mammary Neoplasms, Experimental / Q000737:chemistry*; D051379:Mice; D016513:Mice, SCID; D018482:Muscle, Skeletal / Q000737:chemistry; D009942:Organometallic Compounds / Q000737:chemistry* / Q000493:pharmacokinetics; D015018:Ytterbium
D003287:Contrast Media; D056831:Coordination Complexes; D009942:Organometallic Compounds; C572942:ytterbium(III)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid 10-o-aminoanilide; D015018:Ytterbium